Skip to Main Content

Paper Details

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
Clin Lymphoma Myeloma Leuk
43
2019
Author NameAffiliation
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Keith A BaggerlyUniversity of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2